Compare AbbVie Inc (ABBV) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Solaredge Technologies Inc — how do they compare? AbbVie Inc trades at $253.65 (market cap $449.91B), while Solaredge Technologies Inc trades at $49.66 (market cap $3.22B). The key difference: AbbVie Inc is far larger — about 139.7× Solaredge Technologies Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Solaredge Technologies Inc pays none. Which is the better fit depends on your goals.
| ABBV | SEDG | |
|---|---|---|
Market Cap | $449.91B | $3.22B |
Sector | Health | Technology |
52-Week High | $261.07 | $78.51 |
52-Week Low | $184.85 | $24.42 |
Enterprise Value | $513.38B | $3.15B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
SolarEdge Technologies (SEDG) trades at $52.94, up 1.07% on the day, with a bullish technical signal from moving averages and recent positive momentum in solar stocks. The company reported Q1 2026 earnings that missed expectations, with a net loss of $405.45 million on $1.18 billion revenue. Despite negative profitability metrics, SEDG has beaten earnings estimates in two of the last three quarters. Recent news highlights sector-wide gains driven by AI data center power demand and analyst optimism.
The outlook remains mixed: strong solar industry tailwinds and operational cash flow improvement offer potential upside, but persistent net losses, high debt, and competitive pressures pose significant risks. Analyst consensus is cautious with a $32.11 price target below current levels, reflecting concerns over profitability and execution challenges in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
